Burford Capital (BUR) Given “Sell” Rating at Canaccord Genuity

Share on StockTwits

Burford Capital (LON:BUR)‘s stock had its “sell” rating reaffirmed by analysts at Canaccord Genuity in a note issued to investors on Wednesday. They currently have a GBX 1,543 ($20.16) target price on the stock. Canaccord Genuity’s price objective would suggest a potential downside of 17.49% from the stock’s current price.

Several other research analysts also recently weighed in on the company. Liberum Capital restated a “buy” rating and set a GBX 2,300 ($30.05) target price on shares of Burford Capital in a research note on Friday, January 25th. Numis Securities restated a “buy” rating and set a GBX 2,300 ($30.05) target price on shares of Burford Capital in a research note on Wednesday, December 19th. Finally, Berenberg Bank restated a “buy” rating and set a GBX 2,070 ($27.05) target price on shares of Burford Capital in a research note on Wednesday. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of GBX 2,026 ($26.47).

Shares of BUR stock opened at GBX 1,870 ($24.43) on Wednesday. Burford Capital has a 1-year low of GBX 1,166 ($15.24) and a 1-year high of GBX 2,075 ($27.11). The company has a current ratio of 6.58, a quick ratio of 6.55 and a debt-to-equity ratio of 68.55. The firm has a market cap of $4.09 billion and a P/E ratio of 14.09.

About Burford Capital

Burford Capital Limited is a global finance company focused on law. The Company provides investment capital, investment management, financing and risk solutions with a focus on the litigation and arbitration sector. The Company’s segments include provision of litigation investment, provision of litigation insurance, exploration of new initiatives related to application of capital to the litigation and arbitration sector until such time as those initiatives mature into full-fledged independent segments and investment management activities.

Recommended Story: Stock Split

Analyst Recommendations for Burford Capital (LON:BUR)

Receive News & Ratings for Burford Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burford Capital and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AtriCure  Rating Increased to Buy at BidaskClub
AtriCure Rating Increased to Buy at BidaskClub
Adverum Biotechnologies  Stock Rating Upgraded by Zacks Investment Research
Adverum Biotechnologies Stock Rating Upgraded by Zacks Investment Research
PennyMac Mortgage Investment Trust  Receives Average Recommendation of “Buy” from Analysts
PennyMac Mortgage Investment Trust Receives Average Recommendation of “Buy” from Analysts
Critical Review: Bright Mountain Media  & PROS
Critical Review: Bright Mountain Media & PROS
Veracyte  Raised to “Buy” at BidaskClub
Veracyte Raised to “Buy” at BidaskClub
Zynerba Pharmaceuticals  Rating Increased to Buy at ValuEngine
Zynerba Pharmaceuticals Rating Increased to Buy at ValuEngine


© 2006-2019 Ticker Report